Infographic: The History of Pandemics, by Death Toll
Connect with us

Healthcare

Visualizing the History of Pandemics

Published

on

Article/Editing:

Graphics/Design:

Can I share this graphic?
Yes. Visualizations are free to share and post in their original form across the web—even for publishers. Please link back to this page and attribute Visual Capitalist.
When do I need a license?
Licenses are required for some commercial uses, translations, or layout modifications. You can even whitelabel our visualizations. Explore your options.
Interested in this piece?
Click here to license this visualization.

The History of Pandemics

Pan·dem·ic /panˈdemik/ (of a disease) prevalent over a whole country or the world.

As humans have spread across the world, so have infectious diseases. Even in this modern era, outbreaks are nearly constant, though not every outbreak reaches pandemic level as COVID-19 has.

Today’s visualization outlines some of history’s most deadly pandemics, from the Antonine Plague to the current COVID-19 event.

A Timeline of Historical Pandemics

Disease and illnesses have plagued humanity since the earliest days, our mortal flaw. However, it was not until the marked shift to agrarian communities that the scale and spread of these diseases increased dramatically.

Widespread trade created new opportunities for human and animal interactions that sped up such epidemics. Malaria, tuberculosis, leprosy, influenza, smallpox, and others first appeared during these early years.

The more civilized humans became – with larger cities, more exotic trade routes, and increased contact with different populations of people, animals, and ecosystems – the more likely pandemics would occur.

Here are some of the major pandemics that have occurred over time:

NameTime periodType / Pre-human hostDeath toll
Antonine Plague165-180Believed to be either smallpox or measles5M
Japanese smallpox epidemic735-737Variola major virus1M
Plague of Justinian541-542Yersinia pestis bacteria / Rats, fleas30-50M
Black Death1347-1351Yersinia pestis bacteria / Rats, fleas200M
New World Smallpox Outbreak1520 – onwardsVariola major virus56M
Great Plague of London1665Yersinia pestis bacteria / Rats, fleas100,000
Italian plague1629-1631Yersinia pestis bacteria / Rats, fleas1M
Cholera Pandemics 1-61817-1923V. cholerae bacteria1M+
Third Plague1885Yersinia pestis bacteria / Rats, fleas12M (China and India)
Yellow FeverLate 1800sVirus / Mosquitoes100,000-150,000 (U.S.)
Russian Flu1889-1890Believed to be H2N2 (avian origin)1M
Spanish Flu1918-1919H1N1 virus / Pigs40-50M
Asian Flu1957-1958H2N2 virus1.1M
Hong Kong Flu1968-1970H3N2 virus1M
HIV/AIDS1981-presentVirus / Chimpanzees25-35M
Swine Flu2009-2010H1N1 virus / Pigs200,000
SARS2002-2003Coronavirus / Bats, Civets770
Ebola2014-2016Ebolavirus / Wild animals11,000
MERS2015-PresentCoronavirus / Bats, camels850
COVID-192019-PresentCoronavirus – Unknown (possibly pangolins)6.9M (Johns Hopkins University estimate as of March 1, 2023)

Note: Many of the death toll numbers listed above are best estimates based on available research. Some, such as the Plague of Justinian and Swine Flu, are subject to debate based on new evidence.

Despite the persistence of disease and pandemics throughout history, there’s one consistent trend over time – a gradual reduction in the death rate. Healthcare improvements and understanding the factors that incubate pandemics have been powerful tools in mitigating their impact.

March 1, 2023 Update: Due to popular request, we’ve also visualized how the death tolls of each pandemic stack up as a share of total estimated global populations at the time.

Wrath of the Gods

In many ancient societies, people believed that spirits and gods inflicted disease and destruction upon those that deserved their wrath. This unscientific perception often led to disastrous responses that resulted in the deaths of thousands, if not millions.

In the case of Justinian’s plague, the Byzantine historian Procopius of Caesarea traced the origins of the plague (the Yersinia pestis bacteria) to China and northeast India, via land and sea trade routes to Egypt where it entered the Byzantine Empire through Mediterranean ports.

Despite his apparent knowledge of the role geography and trade played in this spread, Procopius laid blame for the outbreak on the Emperor Justinian, declaring him to be either a devil, or invoking God’s punishment for his evil ways. Some historians found that this event could have dashed Emperor Justinian’s efforts to reunite the Western and Eastern remnants of the Roman Empire, and marked the beginning of the Dark Ages.

Luckily, humanity’s understanding of the causes of disease has improved, and this is resulting in a drastic improvement in the response to modern pandemics, albeit slow and incomplete.

Importing Disease

The practice of quarantine began during the 14th century, in an effort to protect coastal cities from plague epidemics. Cautious port authorities required ships arriving in Venice from infected ports to sit at anchor for 40 days before landing — the origin of the word quarantine from the Italian “quaranta giorni”, or 40 days.

One of the first instances of relying on geography and statistical analysis was in mid-19th century London, during a cholera outbreak. In 1854, Dr. John Snow came to the conclusion that cholera was spreading via tainted water and decided to display neighborhood mortality data directly on a map. This method revealed a cluster of cases around a specific pump from which people were drawing their water from.

While the interactions created through trade and urban life play a pivotal role, it is also the virulent nature of particular diseases that indicate the trajectory of a pandemic.

Tracking Infectiousness

Scientists use a basic measure to track the infectiousness of a disease called the reproduction number — also known as R0 or “R naught.” This number tells us how many susceptible people, on average, each sick person will in turn infect.

Diagram showing R0, or how many people are infected on average by someone with a specific virus

Measles tops the list, being the most contagious with a R0 range of 12-18. This means a single person can infect, on average, 12 to 18 people in an unvaccinated population.

While measles may be the most virulent, vaccination efforts and herd immunity can curb its spread. The more people are immune to a disease, the less likely it is to proliferate, making vaccinations critical to prevent the resurgence of known and treatable diseases.

It’s hard to calculate and forecast the true impact of COVID-19, as the outbreak is still ongoing and researchers are still learning about this new form of coronavirus.

Urbanization and the Spread of Disease

We arrive at where we began, with rising global connections and interactions as a driving force behind pandemics. From small hunting and gathering tribes to the metropolis, humanity’s reliance on one another has also sparked opportunities for disease to spread.

Urbanization in the developing world is bringing more and more rural residents into denser neighborhoods, while population increases are putting greater pressure on the environment. At the same time, passenger air traffic nearly doubled in the past decade. These macro trends are having a profound impact on the spread of infectious disease.

As organizations and governments around the world ask for citizens to practice social distancing to help reduce the rate of infection, the digital world is allowing people to maintain connections and commerce like never before.

Editor’s Note: The COVID-19 pandemic is in its early stages and it is obviously impossible to predict its future impact. This post and infographic are meant to provide historical context, and we will continue to update it as time goes on to maintain its accuracy.

Update (March 1, 2023): We’ve adjusted the death toll for COVID-19, and will continue to update on a regular basis.

Healthcare

Ranked: America’s Most Expensive Drugs

America’s most expensive drugs now top $4 million per dose. See why gene therapies carry record-breaking price tags.

Published

on

This cropped chart ranks America's most expensive drugs in 2025, using data from Fierce Pharma published 2025.

Ranked: America’s Most Expensive Drugs

This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.

Key Takeaways

  • Lenmeldy is America’s priciest drug in 2025 at $4.25 million per dose.
  • One Lenmeldy treatment equals roughly 12,500 Ozempic doses ($342 each, before insurance)

In 2025, the soaring cost of cutting-edge gene therapies has pushed individual drug prices to record highs.

The latest ranking of America’s most expensive drugs highlights how a single treatment can rival the price of a luxury home.

The data for this visualization comes from Fierce Pharma. It lists the 10 priciest U.S. drugs, all topping $2 million per course and most offering one-time, potentially curative benefits

Gene Therapies Dominate the Leaderboard

Lenmeldy, a treatment for the ultrarare disorder metachromatic leukodystrophy, costs $4.25 million per dose, eclipsing every other therapy launched to date.

RankDrug NameCost Per DoseCompanyUsed For
1Lenmeldy$4,250,000Kyowa KirinA gene therapy used
to treat kids with
metachromatic
leukodystrophy
(MLD), a rare
inherited metabolic
disorder
2Kebilidi$3,950,000PTC Therapeutics A gene therapy used
to treat children &
adults with AADC
deficiency, a rare
disorder that prevents
the body from making
key brain chemicals
3Hemgenix$3,500,000CSL BehringA one-time gene
therapy used to treat
adults with
hemophilia B to
reduce bleeding
episodes
4Elevidys$3,200,000Sarepta TherapeuticsA gene therapy used
to treat Duchenne
muscular dystrophy
(DMD) in people 4
years and older
5Lyfgenia$3,100,000bluebird bioA one-time gene
therapy used to treat
sickle cell disease
with a history of pain
crises
6Skysona$3,000,000bluebird bio A gene therapy used
to slow nerve damage
in boys with early,
active cerebral
adrenoleukodystrophy
(CALD)
7Roctavian$2,900,000BioMarinA one-time gene
therapy used to treat
adults with severe
hemophilia A who
don’t have AAV5
antibodies
8Rethymic$2,810,000Sumitomo PharmaA tissue-based
therapy used to help
kids with congenital
athymia build a
working immune
system
9Zynteglo$2,800,000bluebird bioA gene therapy used
to treat people with
transfusion
dependent beta
thalassemia
10Zolgensma$2,320,000NovartisA one-time gene
therapy used to treat
children under 2 with
spinal muscular
atrophy (SMA)

Note: Bluebird Bio is now Genetix Biotherapeutics after acquisition by two private equity firms.

Lenmeldy’s list price equals roughly 12,500 doses of popular diabetes drug Ozempic at its pre-insurance list price.

While the number seems astronomical, payers weigh it against lifelong care costs that can exceed $10 million for untreated MLD patients.

Similarly, third-ranked Hemgenix’s one-time $3.5 million cost compares with up to $20 million for decades of clotting-factor infusions.

Even at multimillion-dollar stickers, pay-once gene therapies can offer health-economic value over chronic treatments.

In fact, every drug on the top 10 list is a gene or cell-based therapy—scientific breakthroughs that replace or repair faulty genetic instructions.

Because they aim to cure rare and deadly conditions in a single dose, their development and manufacturing pipelines are complex, bespoke, and expensive.

ℹ️ Related: Check out where Ozempic ranks in America’s most common drugs by medicare spending.

Bluebird Bio’s Three-Drug Footprint

No company appears more often than Bluebird Bio, which places Lyfgenia, Skysona, and Zynteglo on the list.

Each addresses a different inherited blood or metabolic disorder, yet all share core technology roots developed over a decade.

Despite regulatory scrutiny and manufacturing setbacks, the company’s persistence has translated into multiple FDA approvals.

The cluster illustrates how a single firm can dominate a high-value therapeutic niche.

Bluebird Bio was acquired in June, 2025 by private equity firms Carlyle Group and SK Capital.

Learn More on the Voronoi App

For related coverage, check out Where Americans Pay the Most (and Least) for Health Insurance on Voronoi, the new app from Visual Capitalist.

Continue Reading

Business

Ranked: America’s Most Common Drugs by Medicare Spending

Looking at what’s shaping U.S. healthcare trends by sifting through data about America’s most common drugs by Medicare spending, who manufactures them, and how much they cost.

Published

on

This cropped graphic ranks America's most common drugs, by Medicare spending in 2023.

Ranked: America’s Most Common Drugs by Medicare Spending

This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.

Key Takeaways

  • Eliquis tops 2023 Medicare spending at $18.3 billion, more than twice the second-ranked drug (Ozempic).
  • An aging population—and related conditions like blood clots—are reshaping U.S. healthcare costs.
  • The top 35 drugs by Medicare spending are produced by just 20 companies, highlighting the market’s concentration and pricing power.

From diabetes injectables to blockbuster blood thinners, a handful of drugs account for a sizable share of Medicare’s pharmacy bill.

This visualization ranks the most common drugs by total Medicare spending in 2023, sourced from Centers for Medicare & Medicaid Services

It tracks every claim, dosage, and dollar flowing through Medicare Part D, the federal prescription-drug benefit.

Blood Thinners Are America’s Most Common Drug

Eliquis (generic name: Apixaban) alone racked up $18.3 billion in Medicare spending in 2023, nearly double the next drug, Ozempic.

Alongside Xarelto, anticoagulants accounted for over $24 billion in 2023.

RankDrug NameCompanyTotal Medicare
Spending (2023)
Prevents / Treats
1EliquisBMS Primarycare$18,273,451,967Blood clots
2OzempicNovo Nordisk$9,194,048,435Diabetes, weight loss
3JardianceBoehringer Ing.$8,839,935,063Diabetes
4TrulicityEli Lilly & Co.$7,363,856,224Diabetes
5XareltoJanssen Pharm.$6,309,246,823Blood clots
6Trelegy ElliptaGlaxosmithkline$4,455,884,010COPD
7Humira(Cf) PenAbbvie US LLC$4,419,828,188Arthritis, Crohn's disease
8FarxigaAstrazeneca$4,342,182,307Diabetes
9JanuviaMerck Sharp & D$4,090,836,821Diabetes
10RevlimidCelgene/BMS$3,859,804,789Blood cancers & bone marrow disease
11EntrestoNovartis$3,430,441,590Heart failure
12Lantus SolostarSanofi-Aventis$3,157,233,282Diabetes
13BiktarvyGilead Sciences$3,152,256,269HIV infection
14Stelara*Janssen Biotech*$2,987,778,600Psoriasis, psoriatic arthritis, Crohn's disease
15XtandiAstellas Pharma$2,601,510,278Prostate cancer
16MyrbetriqAstellas Pharma$2,510,288,600Overactive bladder
17ImbruvicaPharmacyclics,$2,371,893,292Blood cancers
18MounjaroEli Lilly & Co.$2,361,384,157Diabetes, weight loss
19Enbrel SureclickAmgen$2,054,858,499Various kind of arthritis
20IbrancePfizer US Pharm$2,020,903,604Breast cancer
21SymbicortAstrazeneca$2,004,295,918Asthma, COPD
22JakafiIncyte Corporat$1,940,765,069Bone marrow disorders
23Novolog FlexpenNovo Nordisk$1,875,605,627Diabetes
24OfevBoehringer Ing.$1,837,061,150Pulmonary fibrosis
25LinzessAllergan Inc.$1,825,245,843IBS, constipation
26Invega SustennaJanssen Pharm.$1,821,418,393Schizophrenia
27PomalystCelgene/BMS$1,709,288,465Blood cancers
28IngrezzaNeurocrine Bios$1,705,132,723Huntington’s disease
29LenalidomideAmneal Pharmaceuticals / Sun Pharma / Teva Pharmaceuticals$1,681,292,157Blood cancers & bone marrow disease
30RybelsusNovo Nordisk$1,665,906,943Diabetes, weight loss
31RestasisAllergan Inc.$1,501,664,198Chronic dry eye
32CreonAbbvie US LLC$1,466,866,603Pancreatic enzyme replacement
33ArexvyGlaxosmithkline$1,387,933,256RSV prevention
34Breo ElliptaGlaxosmithkline$1,373,600,714Asthma, COPD
35VyndamaxPfizer US Pharm$1,349,659,508Amyloid heart disease

Their rise reflects both an aging population and expanding preventative treatment for stroke and atrial fibrillation.

With almost four million beneficiaries, Eliquis is prescribed to roughly one in 10 Part D enrollees.

ℹ️ Related: See the 25 countries that are projected have the most seniors in 2050.

Diabetes and Weight-Loss Therapies Surge in America

Four GLP-1 and SGLT2 diabetes drugs—Ozempic, Jardiance, Trulicity, and Farxiga—collectively totaled $29.7 billion.

Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro also double as weight-loss aids, driving demand beyond traditional type-2 diabetes patients.

This (sortable table) lists cost per dose for the top 35 drugs.

RankDrug NameCompanyGeneric Name# of BeneficiariesMedicare Spending Per Dosage Unit
1EliquisBMS PrimarycareApixaban3,927,848$10
2OzempicNovo NordiskSemaglutide1,464,468$356
3JardianceBoehringer Ing.Empagliflozin1,882,768$20
4TrulicityEli Lilly & Co.Dulaglutide938,731$483
5XareltoJanssen Pharm.Rivaroxaban1,324,165$18
6Trelegy ElliptaGlaxosmithklineFluticasone/Umeclidin/Vilanter1,050,583$11
7Humira(Cf) PenAbbvie US LLCAdalimumab61,474$3,750
8FarxigaAstrazenecaDapagliflozin Propanediol993,909$20
9JanuviaMerck Sharp & DSitagliptin Phosphate843,391$19
10RevlimidCelgene/BMSLenalidomide36,967$878
11EntrestoNovartisSacubitril/Valsartan663,587$12
12Lantus SolostarSanofi-AventisInsulin Glargine,Hum.Rec.Anlog1,198,294$30
13BiktarvyGilead SciencesBictegrav/Emtricit/Tenofov Ala83,843$133
14Stelara*Janssen Biotech*Ustekinumab22,930$26,818
15XtandiAstellas PharmaEnzalutamide28,658$146
16MyrbetriqAstellas PharmaMirabegron769,978$15
17ImbruvicaPharmacyclics,Ibrutinib17,100$487
18MounjaroEli Lilly & Co.Tirzepatide370,203$540
19Enbrel SureclickAmgenEtanercept34,287$1,812
20IbrancePfizer US PharmPalbociclib16,015$753
21SymbicortAstrazenecaBudesonide/Formoterol Fumarate984,400$39
22JakafiIncyte CorporatRuxolitinib Phosphate14,041$298
23Novolog FlexpenNovo NordiskInsulin Aspart588,526$39
24OfevBoehringer Ing.Nintedanib Esylate20,444$221
25LinzessAllergan Inc.Linaclotide565,088$18
26Invega SustennaJanssen Pharm.Paliperidone Palmitate70,988$2,344
27PomalystCelgene/BMSPomalidomide12,739$1,089
28IngrezzaNeurocrine BiosValbenazine Tosylate29,191$268
29LenalidomideAmneal Pharmaceuticals / Sun Pharma / Teva PharmaceuticalsLenalidomide20,403$682
30RybelsusNovo NordiskSemaglutide285,693$32
31RestasisAllergan Inc.Cyclosporine492,479$11
32CreonAbbvie US LLCLipase/Protease/Amylase185,325$9
33ArexvyGlaxosmithklineRsvpref3 Antigen/As01e/PF4,390,151$316
34Breo ElliptaGlaxosmithklineFluticasone/Vilanterol556,799$7
35VyndamaxPfizer US PharmTafamidis7,589$735

Their high list prices—Ozempic averages $356 per dose—illustrate how novel biologics multiply spending even with smaller patient counts.

ℹ️ Related: See where Americans skipped going to the doctor (even when they had to) in 2023.

Cancer and Autoimmune Biologics are Expensive Drugs

Revlimid, Humira, and Stelara each exceed $3 billion despite treating fewer than 100,000 beneficiaries each.

Revlimid’s $878 per dose and Stelara’s staggering $26,818 underscore why biologics dominate specialty-drug budgets.

Learn More on the Voronoi App

Want more health-related data storytelling? Check out Ranked: Countries That Spend the Most Years in Poor Health on Voronoi, the new app from Visual Capitalist.

Continue Reading

Popular